KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Inovio Pharmaceuticals (INO) over the last 16 years, with Q3 2025 value amounting to $138278.0.

  • Inovio Pharmaceuticals' Change in Receivables rose 5523.95% to $138278.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$884149.0, marking a year-over-year decrease of 21413.4%. This contributed to the annual value of -$1.2 million for FY2024, which is 8707.63% up from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Change in Receivables stood at $138278.0 for Q3 2025, which was up 5523.95% from -$469925.0 recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Receivables peaked at $3.9 million during Q2 2022, and registered a low of -$8.8 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Receivables was $81120.0 (2023), whereas its average is -$951850.5.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 116171.86% in 2021, then skyrocketed by 10299.71% in 2024.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Receivables (Quarter) stood at $906955.0 in 2021, then skyrocketed by 82.76% to $1.7 million in 2022, then crashed by 84.25% to $261033.0 in 2023, then tumbled by 354.25% to -$663683.0 in 2024, then soared by 120.83% to $138278.0 in 2025.
  • Its Change in Receivables was $138278.0 in Q3 2025, compared to -$469925.0 in Q2 2025 and $111181.0 in Q1 2025.